Not everyone is automatically eligible for Wegovy based on their BMI alone
Passwater: Ive always called GSH the foot-soldier of our antioxidant defenses
CrossRef GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications Sedat Arslan, Ayca Aydin Academia Oncology.2026;[Epub] CrossRef From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies R
The table below summarises the practical differences people most often ask about
[7], in a recent meta-analysis of 27 RCTs, found no difference in cancer incidence between sodium-glucose cotransporter-2 inhibitors and comparators, including placebo
For example, in 2008, researchers in China undertook a three-month trial to assess the hypoglycemic effect of berberine versus metformin, a common prescription used to control the blood sugar levels in people with type 2 diabetes